Bernhard Hampl, Ph.D. joined Great Point Partners’ CEO Advisory Board in 2011. He is the Co-Chairman of the Board of Directors of the GPP II portfolio company, Softbox and was previously the Co-Chairman of the Board of Directors of GPP I portfolio company, Cytovance Biologics.
Dr. Hampl is President of BKH Pharma-Services and currently on the Board of Chenwerth, a leading Active Pharmaceutical Ingredient ("API") provider to the pharmaceutical industry. Previously, Dr. Hampl was Executive Chairman of the Board of APP / Fresenius Kabi U.S. from 2009 to 2012. Prior to that, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until its acquisition by Novartis in a $2.8 billion deal, at which time he became the CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million. He is also a minority investor in several start-up pharmaceutical companies.
Dr. Hampl earned a Ph.D. in pharmaceutical chemistry from the Ludwig Maximilian University of Munich, Germany, School of Chemistry and Pharmacy.
- Sandoz US-division of Novartis – biosimilar, biologic and generic pharmaceuticals
- Eon Labs – specialty pharmaceuticals